Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-07-15FDA Approved: PREGABALIN — Original Application (Tris Pharma Inc)
The FDA approved Tris Pharma's original Abbreviated New Drug Application for pregabalin, allowing a generic pregabalin product to enter the …
-
FDA approval · 2021-06-29FDA Approved: ESLICARBAZEPINE ACETATE — Original Application (Dr.Reddys Laboratories Inc)
FDA approved a generic eslicarbazepine acetate through an Original Application for Dr. Reddy's Laboratories, providing a generic option for …
-
FDA approval · 2021-06-11FDA Approved: LEVETIRACETAM — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original application (ANDA) for LEVETIRACETAM by ScieGen Pharmaceuticals, authorizing the generic product.
-
FDA approval · 2021-04-13FDA Approved: PREGABALIN — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the original abbreviated new drug application for pregabalin from Novadoz Pharmaceuticals LLC, enabling a generic version of pr…
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: Phase II BGG492 Capsule Extension for Partial Epilepsy [Phase 2]
Phase II extension trial update for BGG492 capsule in partial epilepsy (partial onset seizures) completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-01-26FDA Approved: ZONISAMIDE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved Unichem Pharmaceuticals (USA), Inc.'s generic zonisamide product through an Abbreviated New Drug Application, confirming a gene…
-
FDA approval · 2021-01-19FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for LEVETIRACETAM filed by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures [Phase 2]
Phase 2 trial update on BGG492 as adjunctive treatment for partial onset seizures reports efficacy and safety findings.
-
FDA approval · 2020-11-27FDA Approved: LEVETIRACETAM ER — Original Application (Westminster Pharmaceuticals, LLC)
FDA approved Westminster Pharmaceuticals' generic extended-release levetiracetam tablet (LEVETIRACETAM ER) under an Original Abbreviated New…
-
FDA approval · 2020-11-05FDA Approved: OXCARBAZEPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for oxcarbazepine from Sun Pharmaceutical Industries, Inc., resulting in an approved labeling change…
-
FDA approval · 2020-09-30FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA XR (levetiracetam), the extended-release formulation, submitted by UCB, Inc.
-
FDA approval · 2020-08-26FDA Approved: OXCARBAZEPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for oxcarbazepine filed by Sun Pharmaceutical Industries, Inc. (ANDA077794).
-
CLINICAL_TRIALS trial_result · 2020-08-13Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures [Phase 3]
Phase 3 trial assessing long-term adjunctive lacosamide in adults with partial-onset seizures; study completed with results posted in 2020.
-
FDA approval · 2020-06-11FDA Approved: LEVETIRACETAM EXTENDED-RELEASE — Original Application (Omnivium Pharmaceuticals LLC)
FDA approved an extended-release generic formulation of levetiracetam (ANDA212688) manufactured by Omnivium Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures [Phase 3]
Phase 3 study of perampanel (E2007) as adjunctive therapy in refractory partial-onset seizures completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-04-06Clinical Trial Update: Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures [Phase 3]
Phase 3 trial update for perampanel as adjunctive therapy in pediatric partial onset seizures or primary generalized tonic-clonic seizures; …
-
FDA approval · 2020-04-03FDA Approved: LYRICA CR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental NDA for LYRICA CR (pregabalin) submitted by Viatris Specialty LLC, indicating a regulatory approval of a supplem…
-
FDA approval · 2020-03-23FDA Approved: PREGABALIN — Original Application (Creekwood Pharmaceuticals LLC)
FDA approves Creekwood Pharmaceuticals LLC's Original Application (ANDA) for pregabalin, enabling a generic version of the drug. This action…
-
CLINICAL_TRIALS trial_result · 2020-02-25Clinical Trial Update: Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study) [Phase 3]
Phase 3 trial evaluating perampanel monotherapy for partial onset seizures has completed with results posted.
-
FDA approval · 2019-11-29FDA Approved: PREGABALIN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved the original ANDA for pregabalin from Sun Pharmaceutical Industries, authorizing a generic version of pregabalin.
-
FDA approval · 2019-11-21FDA Approved: XCOPRI — Original Application (SK Life Science, Inc.)
FDA approved XCOPRI (cenobamate) from SK Life Science, Inc. in an original NDA for adjunctive treatment of partial-onset seizures in adults …
-
CLINICAL_TRIALS trial_result · 2019-11-15Clinical Trial Update: Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [Phase 2, Phase 3]
A long-term safety and tolerability update of TRI476 (oxcarbazepine) in children with inadequately controlled partial onset seizures from a …
-
FDA approval · 2019-10-08FDA Approved: PREGABALIN — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' original Abbreviated New Drug Application for pregabalin, a generic version of the brand product.
-
FDA approval · 2019-07-19FDA Approved: PREGABALIN — Original Application (Cipla USA, Inc.)
FDA approves Cipla USA, Inc.'s original application for pregabalin, granting a generic version of the drug for its established indications.
-
FDA approval · 2019-07-19FDA Approved: PREGABALIN — Original Application (ScieGen Pharmaceuticals, Inc)
FDA approves ScieGen Pharmaceuticals' original application for pregabalin (generic pregabalin), enabling the generic product to be marketed …